Share Twitter LinkedIn Facebook Email Dr. Daniel Goldstein reviews data by Drs. Gulley & colleagues on PROSTVAC vaccine in metastatic prostate cancer & discusses the implications of trials that fail in phase III despite looking extremely favorable in phase II studies.
MOASC Awards $25,000 Research Grant from AVEO Oncology to Dr. Peter Zang, MD of City of Hope 2025 Cary Presant, MD Investigator Award Prostate 4 Mins Read
Overview of SYNC-T Technology from Syncromune in Prostate Cancer Treatment – Charles Link, MD Prostate 2 Mins Read